Secondary Structure of Huntingtin Amino-Terminal Region

Structure

Volumn 17, Issue 9, 2009, Pages 1205-1212

  Kim, Mee Whi ^a   Chelliah, Yogarany ^b   Kim, Sang Woo ^b   Otwinowski, Zbyszek ^a   Bezprozvanny, Ilya ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

HUMDISEASE; PROTEINS

Indexed keywords

AMYLOID PROTEIN; HUNTINGTIN; POLYGLUTAMIC ACID; POLYPROLINE; PROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; CELL INTERACTION; EXON; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 69849086690     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2009.08.002     Document Type: Article

References (48)

1. Altschuler E.L., Hud N.V., Mazrimas J.A., and Rupp B. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J. Pept. Res. 50 (1997) 73-75
2. Armen R.S., Bernard B.M., Day R., Alonso D.O., and Daggett V. Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 102 (2005) 13433-13438
3. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., and Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16 (2007) 2600-2615
4. Bennett M.J., Huey-Tubman K.E., Herr A.B., West Jr. A.P., Ross S.A., and Bjorkman P.J. Inaugural Article: A linear lattice model for polyglutamine in CAG-expansion diseases. Proc. Natl. Acad. Sci. USA 99 (2002) 11634-11639
5. Bevivino A.E., and Loll P.J. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc. Natl. Acad. Sci. USA 98 (2001) 11955-11960
6. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15 (2009) 89-100
7. Bhattacharyya A., Thakur A.K., Chellgren V.M., Thiagarajan G., Williams A.D., Chellgren B.W., Creamer T.P., and Wetzel R. Oligoproline effects on polyglutamine conformation and aggregation. J. Mol. Biol. 355 (2006) 524-535
8. Blondelle S.E., Forood B., Houghten R.A., and Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. Biochemistry 36 (1997) 8393-8400
9. Center R.J., Kobe B., Wilson K.A., Teh T., Howlett G.J., Kemp B.E., and Poumbourios P. Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein. Protein Sci. 7 (1998) 1612-1619
10. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83 (2007) 228-248
11. Chellgren B.W., Miller A.F., and Creamer T.P. Evidence for polyproline II helical structure in short polyglutamine tracts. J. Mol. Biol. 361 (2006) 362-371
12. Chen S., Berthelier V., Yang W., and Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311 (2001) 173-182
13. Darnell G., Orgel J.P., Pahl R., and Meredith S.C. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J. Mol. Biol. 374 (2007) 688-704
14. Dehay B., and Bertolotti A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J. Biol. Chem. 281 (2006) 35608-35615
15. Duennwald M.L., Jagadish S., Muchowski P.J., and Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc. Natl. Acad. Sci. USA 103 (2006) 11045-11050
16. Fraser P.E., Nguyen J.T., Surewicz W.K., and Kirschner D.A. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60 (1991) 1190-1201
17. Gusella J.F., and MacDonald M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1 (2000) 109-115
18. Kelley N.W., Huang X., Tam S., Spiess C., Frydman J., and Pande V.S. The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. J. Mol. Biol. 388 (2009) 919-927
19. Khare S.D., Ding F., Gwanmesia K.N., and Dokholyan N.V. Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput. Biol. 1 (2005) 230-235
20. Klein F.A., Pastore A., Masino L., Zeder-Lutz G., Nierengarten H., Oulad-Abdelghani M., Altschuh D., Mandel J.L., and Trottier Y. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J. Mol. Biol. 371 (2007) 235-244
21. Lathrop R.H., Casale M., Tobias D.J., Marsh J.L., and Thompson L.M. Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6 (1998) 105-114
22. Legleiter J., Lotz G.P., Miller J., Ko J., Ng C., Williams G.L., Finkbeiner S., Patterson P.H., and Muchowski P.J. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 284 (2009) 21647-21658
23. Li S.H., and Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20 (2004) 146-154
24. Li P., Huey-Tubman K.E., Gao T., Li X., West Jr. A.P., Bennett M.J., and Bjorkman P.J. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat. Struct. Mol. Biol. 14 (2007) 381-387
25. Masino L., Kelly G., Leonard K., Trottier Y., and Pastore A. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 513 (2002) 267-272
26. Minor W., Tomchick D., and Otwinowski Z. Strategies for macromolecular synchrotron crystallography. Structure 8 (2000) R105-110
27. Murphy R.M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 4 (2002) 155-174
28. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., and Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14 (2007) 332-340
29. Nguyen J., Baldwin M.A., Cohen F.E., and Prusiner S.B. Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. Biochemistry 34 (1995) 4186-4192
30. Perutz M.F. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6 (1996) 848-858
31. Perutz M.F., Finch J.T., Berriman J., and Lesk A. Amyloid fibers are water-filled nanotubes. Proc. Natl. Acad. Sci. USA 99 (2002) 5591-5595
32. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., and Thompson L.M. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16 (2007) 61-77
33. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35 (2002) 819-822
34. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18 (2002) 202-209
35. Singer S.J., and Dewji N.N. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc. Natl. Acad. Sci. USA 103 (2006) 1546-1550
36. Takahashi T., Kikuchi S., Katada S., Nagai Y., Nishizawa M., and Onodera O. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17 (2008) 345-356
37. Tanaka M., Morishima I., Akagi T., Hashikawa T., and Nukina N. Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem. 276 (2001) 45470-45475
38. Temussi P.A., Masino L., and Pastore A. From Alzheimer to Huntington: why is a structural understanding so difficult?. EMBO J. 22 (2003) 355-361
39. Thakur A.K., Jayaraman M., Mishra R., Thakur M., Chellgren V.M., Byeon I.J., Anjum D.H., Kodali R., Creamer T.P., Conway J.F., et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16 (2009) 380-389
40. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
41. Tobin A.J., and Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10 (2000) 531-536
42. Truant R., Atwal R.S., Desmond C., Munsie L., and Tran T. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 275 (2008) 4252-4262
43. Tsukamoto K., Shimizu H., Ishida T., Akiyama Y., and Nukina N. Aggregation mechanism of polyglutamine disease revealed using quantum chemical calculations, fragment molecular orbital calculations, molecular dynamics simulations, and binding free energy calculations. J. Mol. Struct. 778 (2006) 85-95
44. Uversky V.N., and Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698 (2004) 131-153
45. Vitalis A., Wang X., and Pappu R.V. Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization. J. Mol. Biol. 384 (2008) 279-297
46. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
47. Wang X., Vitalis A., Wyczalkowski M.A., and Pappu R.V. Characterizing the conformational ensemble of monomeric polyglutamine. Proteins 63 (2006) 297-311
48. Williams A.J., and Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31 (2008) 521-528